贝前列素联合纤溶酶治疗下肢动脉硬化闭塞症的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 贝前列素联合纤溶酶治疗下肢动脉硬化闭塞症的临床观察
TITLE:
摘要: 目的:观察贝前列素联合纤溶酶治疗下肢动脉硬化闭塞症(LEAOD)的临床疗效及安全性。方法:选择2015年1月-2016年1月于我院接受治疗的82例LEAOD患者,采用随机数字表法分为对照组和观察组,各41例。所有患者在原发疾病的治疗基础上均给予低盐、低脂饮食。对照组患者另给予纤溶酶注射液200单位,ivgtt,qd;观察组患者在对照组基础上加用贝前列素钠片40 μg,tid,饭后服用。两组患者均治疗15 d。比较两组患者的临床疗效,治疗前后的血液流变学指标、踝肱指数、疼痛评分、冷感评分、间歇跛行评分和血清氧化应激指标,记录不良反应发生情况。结果:观察组患者的总有效率(90.24%)明显高于对照组(78.05%),差异有统计学意义(P<0.05)。治疗前,两组患者上述指标比较,差异均无统计学意义(P>0.05);治疗后,两组患者的全血高切黏度、血浆黏度、血细胞比容、纤维蛋白原含量、血小板黏附率、疼痛评分、冷感评分、间歇跛行评分和血清丙二醛水平均较治疗前明显降低,踝肱指数、血清超氧化物歧化酶水平、总抗氧化能力和血清谷胱甘肽过氧化物酶水平均较治疗前明显升高,且观察组各指标均明显优于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:贝前列素联合纤溶酶治疗LEAOD的疗效较好,能够有效缓解患者临床症状、促进其局部血液循环、改善其氧化应激水平,且安全性较高。
ABSTRACT: OBJECTIVE: To observe the clinical efficacy and safety of beraprost combined with fibrinogenase in the treatment of lower extremity atherosclerotic occlusive disease (LEAOD). METHODS: A total of 82 LEAOD patients selected from our hospital during Jan. 2015-Jan. 2016 were divided into control group and observation group according to random number table, with 41 cases in each group. All patients received low salt and low fat diet on the basis of treatment for primary disease. Control group was additionally given Fibrinogenase injection 200 U, ivgtt, qd; observation group was additionally given Beraprost sodium tablets 40 μg,tid, after meal, on the basis of control group. Both groups were treated for 15 d. Clinical efficacies as well as hemorheological indexes, ankle-brachial indexes, pain scores, cold felling scores, intermittent claudication scores and serum oxidation stress indexes before and after treatment were compared between 2 groups. The occurrence of ADR was also recorded. RESULTS: Total response rate of observation group (90.24%) was significantly higher than that of control group (78.05%), with statistical significance (P<0.05). Before treatment, there was no statistical significance in above indexes between 2 groups (P>0.05). Compared to before treatment, whole blood high shear viscosity, plasma viscosity, hematocrit, fibrinogen contents, platelet adhesion rates, pain scores, cold feeling scores, intermittent claudication scores and serum MDA levels of 2 groups were decreased significantly after treatment; while ankle-brachial indexes, the serum levels of SOD, T-AOC and GSH-Px were increased; the indexes of observation group were better than those of control group, with statistical significance (P<0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). CONCLUSIONS: Beraprost combined with fibrinogenase show good therapeutic efficacy for LEAOD, can effectively relieve clinical symptoms, promote local blood circulation and improve oxidant stress level with good safety.
期刊: 2017年第28卷第29期
作者: 安乾,王兵,崔文军,李阳,李攀峰
AUTHORS: AN Qian,WANG Bing,CUI Wenjun,LI Yang,LI Panfeng
关键字: 贝前列素;纤溶酶;下肢动脉硬化闭塞症;氧化应激;血液流变学
KEYWORDS: Beraprost; Fibrinogenase; Lower extremity atherosclerotic occlusive disease; Oxidation stress; Hemorheology
阅读数: 88 次
本月下载数: 5 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!